| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| MT-2765 | MT-2765 | Phase 3 Clinical | Mitsubishi Tanabe Pharma Corp | Hypertension | Details |
| SP-20104 (Sarfez Pharmaceuticals) | SP-20104 | Phase 2 Clinical | 1 A Pharma Gmbh | Glomerulosclerosis, Focal Segmental | Details |
| Imarikiren hydrochloride | TAK-272; SCO-272 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Diabetic Nephropathies; Hepatic Insufficiency; Hypertension; Renal Insufficiency | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Aliskiren Hemifumarate/Amlodipine Besilate/Hydrochlorothiazide | Approved | Novartis Pharma Ag | Rasitrio, Amturnide | United States | Hypertension | null | 2010-12-21 | Essential Hypertension; Hypertension | Details | |
| Sitokiren Malate | MT-2765; MT2765; I-001; SPH-3127; I001-A; I001-B | Approved | Mitsubishi Tanabe Pharma, Shanghai Pharmaceuticals Holding Co Ltd | 信妥安 | Mainland China | Essential Hypertension | Shanghai Sine Pharmaceutical Laboratories Co Ltd | 2025-12-03 | Colitis, Ulcerative; Diabetic Nephropathies; Essential Hypertension; Hypertension; Kidney Diseases; Psoriasis | Details |
| Aliskiren Hemifumarate | CGP-60536; SPP-100; SPP-100B; SPP-100A; CGP-60536B | Approved | Novartis Pharma Ag | Sprimeo, Enviage, Tekturna, Riprazo, 锐思力, Rasilez | United States | Hypertension | Noden Pharma Dac | 2007-03-05 | Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic macular oedema; Diabetic Nephropathies; Essential Hypertension; Glomerulonephritis, IGA; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Myocardial Infarction; Myocardial Ischemia; Overweight | Details |
| Aliskiren | Approved | Mainland China | Essential Hypertension | Novartis Pharma Ag | 2010-03-26 | Essential Hypertension | Details |